OneOncology, a national partnership of community oncology practices, says that its partner practices have begun treating patients with 2 anticancer biosimilars: Kanjinti, a trastuzumab biosimilar referencing Herceptin, and Mvasi, a bevacizumab biosimilar referencing Avastin.
OneOncology, a national partnership of community oncology practices, says that its partner practices have begun treating patients with 2 anticancer biosimilars: Kanjinti, a trastuzumab biosimilar referencing Herceptin, and Mvasi, a bevacizumab biosimilar referencing Avastin.
The products, both made by Amgen, were launched in the United States just last month at list prices that represent 15% discounts off the list prices of their respective reference products, though these list prices do not reflect discounts and rebates.
OneOncology says that it has adopted both of the biosimilars as preferred formulary agents as part of its cost-effectiveness strategy.
Jeffrey Patton, MD, OneOncology’s president of physician services, said in a statement that “Making Mvasi and Kanjinti preferred OneOncology agents gives our physicians immediate access to cutting-edge therapies and reinforces our commitment to leading the oncology marketplace and delivering the highest-quality and most cost-effective care to our patients."
Lee Schwartzberg, MD, chief medical officer of OneOncology, added that, "As we begin to incorporate biosimilar medications into our treatment pathways, we will collaborate with our physicians to navigate the fluctuating healthcare landscape and drive initiatives that ensure our clinicians appropriately utilize the right therapeutic sequence at the right time for the right patient."
News that the group has begun to use biosimilars so shortly after their launch comes as welcome news to biosimilar stakeholders; while anticancer biosimilars, including trastuzumab, are already available and widely used in Europe, concerns have persisted that US clinicians might not be swift to adopt biosimilars. In part, those concerns have been related to historically sluggish biosimilar uptake for products in the rheumatology space, but concerns have also surrounded barriers such as provider mistrust and lack of awareness in the oncology setting.
To help remedy those issues, groups like the American Society of Clinical Oncology have stepped up their educational efforts, including issuing a 2018 statement that offered clinicians guidance on using biosimilars in oncology.
In the European context, the European Society of Medical Oncology has also provided extensive educational materials for clinicians, including a 2018 paper that focuses on the integration of biosimilars into routine oncology practice.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.